LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis - 18/06/20
pages | 7 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | LncRNA MCM3AP-AS1 and CENPF were upregulated in breast cancer. |
• | LncRNA MCM3AP-AS1 functioned as a sponge of miR-28-5p. |
• | CENPF was targeted by miR-28-5p. |
• | MCM3AP-AS1/miR-28-5p/CENPF axis contributed to cell proliferation, migration, invasion and tumor growth in BC. |
Abstract |
Breast cancer is one of the commonly occurred cancers among women and poses a huge threat against female health. Abnormal expression of lncRNA has been confirmed to be an important inducer of cancer. By searching GEO and TCGA database, we found that CENPF was upregulated in breast cancer tissues. Through RT-qPCR, CENPF was found to be upregulated in breast cancer cells. Functional experiments revealed that CENPF had positive effect on the cellular functions, including proliferation, migration and invasion. Subsequently, CENPF was confirmed to combine with miR-28-5p, and its expression was suppressed by miR-28-5p. Furthermore, it was found that miR-28-5p bound to MCM3AP-AS1, and MCM3AP-AS1 expressed at a high level in breast cancer cells. Besides, MCM3AP-AS1 was confirmed as a cytoplasmic RNA. In addition, there was a positive expression correlation between MCM3AP-AS1 and CENPF. Therefore, MCM3AP-AS1 was confirmed to regulate CENPF via competitively binding to miR-28-5p. At last, rescue assays demonstrated that knockdown of CENPF restored miR-28-5p repression-induced cellular processes in MCM3AP-AS1-silenced cells. In vivo assay revealed that MCM3AP-AS1 could hasten tumor growth in breast cancer by targeting CENPF. All results indicated that MCM3AP-AS1/miR-28-5p/CENPF axis accelerates breast cancer progression.
Le texte complet de cet article est disponible en PDF.Keywords : CENPF, miR-28-5p, MCM3AP-AS1, Breast cancer
Plan
Vol 128
Article 110289- août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?